

# Levi A Garraway

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8971154/levi-a-garraway-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

83  
papers

22,958  
citations

57  
h-index

84  
g-index

84  
ext. papers

29,205  
ext. citations

21.9  
avg, IF

6.44  
L-index

#	Paper	IF	Citations
83	Discovery and saturation analysis of cancer genes across 21 tumour types. <i>Nature</i> , <b>2014</b> , 505, 495-501	50.4	1990
82	Integrative clinical genomics of advanced prostate cancer. <i>Cell</i> , <b>2015</b> , 161, 1215-1228	56.2	1765
81	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. <i>Science</i> , <b>2016</b> , 351, 1463-9	33.3	1758
80	Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. <i>Science</i> , <b>2015</b> , 350, 207-211	33.3	1583
79	Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. <i>Genome Medicine</i> , <b>2017</b> , 9, 34	14.4	1509
78	Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. <i>Nature</i> , <b>2005</b> , 436, 117-22	50.4	1127
77	Lessons from the cancer genome. <i>Cell</i> , <b>2013</b> , 153, 17-37	56.2	912
76	Defining a Cancer Dependency Map. <i>Cell</i> , <b>2017</b> , 170, 564-576.e16	56.2	844
75	Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. <i>Nature Medicine</i> , <b>2016</b> , 22, 298-305	50.5	775
74	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , <b>2015</b> , 5, 1164-1177	24.4	581
73	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. <i>Cell</i> , <b>2018</b> , 175, 984-997.e24	56.2	477
72	High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. <i>Cancer Discovery</i> , <b>2012</b> , 2, 82-93	24.4	425
71	Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. <i>Cell Reports</i> , <b>2016</b> , 15, 857-865	10.6	422
70	Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. <i>Nature Medicine</i> , <b>2014</b> , 20, 682-8	50.5	406
69	The long tail of oncogenic drivers in prostate cancer. <i>Nature Genetics</i> , <b>2018</b> , 50, 645-651	36.3	380
68	Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. <i>Cancer Discovery</i> , <b>2014</b> , 4, 1140-53	24.4	361
67	Circumventing cancer drug resistance in the era of personalized medicine. <i>Cancer Discovery</i> , <b>2012</b> , 2, 214-26	24.4	348

66	Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. <i>Cancer Discovery</i> , <b>2016</b> , 6, 914-29	24.4	343
65	A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. <i>Cancer Discovery</i> , <b>2014</b> , 4, 816-27	24.4	338
64	Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. <i>JAMA Oncology</i> , <b>2015</b> , 1, 653-61	13.4	336
63	RNF43 is frequently mutated in colorectal and endometrial cancers. <i>Nature Genetics</i> , <b>2014</b> , 46, 1264-6	36.3	287
62	Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, E5564-73	11.5	275
61	Lineage dependency and lineage-survival oncogenes in human cancer. <i>Nature Reviews Cancer</i> , <b>2006</b> , 6, 593-602	31.3	267
60	MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. <i>Science</i> , <b>2016</b> , 351, 1214-8	33.3	248
59	Institutional implementation of clinical tumor profiling on an unselected cancer population. <i>JCI Insight</i> , <b>2016</b> , 1, e87062	9.9	245
58	ARID1B is a specific vulnerability in ARID1A-mutant cancers. <i>Nature Medicine</i> , <b>2014</b> , 20, 251-4	50.5	243
57	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. <i>Nature Genetics</i> , <b>2011</b> , 43, 964-968	36.3	242
56	Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. <i>Cell Metabolism</i> , <b>2018</b> , 27, 977-987.e4	24.6	241
55	Precision oncology: an overview. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1803-5	2.2	229
54	Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. <i>Cancer Discovery</i> , <b>2018</b> , 8, 196-215	24.4	228
53	Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. <i>Cancer Cell</i> , <b>2014</b> , 26, 813-825	24.3	216
52	Quantitative Proteomics of the Cancer Cell Line Encyclopedia. <i>Cell</i> , <b>2020</b> , 180, 387-402.e16	56.2	210
51	Assessing the clinical utility of cancer genomic and proteomic data across tumor types. <i>Nature Biotechnology</i> , <b>2014</b> , 32, 644-52	44.5	205
50	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 2792-9	7.5	202
49	Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. <i>Nature Medicine</i> , <b>2017</b> , 23, 1063-1071	50.5	169

48	TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer. <i>Cancer Cell</i> , <b>2016</b> , 29, 846-858	24.3	160
47	Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. <i>Cancer Discovery</i> , <b>2018</b> , 8, 1096-1111	24.4	156
46	Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state. <i>Molecular Systems Biology</i> , <b>2017</b> , 13, 905	12.2	133
45	A functional landscape of resistance to ALK inhibition in lung cancer. <i>Cancer Cell</i> , <b>2015</b> , 27, 397-408	24.3	123
44	The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. <i>Genome Medicine</i> , <b>2016</b> , 8, 79	14.4	109
43	Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. <i>American Journal of Human Genetics</i> , <b>2016</b> , 98, 1051-1066	11	107
42	Future cancer research priorities in the USA: a Lancet Oncology Commission. <i>Lancet Oncology</i> , <b>2017</b> , 18, e653-e706	21.7	106
41	IFN $\gamma$ -Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment. <i>Cell</i> , <b>2017</b> , 170, 127-141.e15	56.2	104
40	Reduced local mutation density in regulatory DNA of cancer genomes is linked to DNA repair. <i>Nature Biotechnology</i> , <b>2014</b> , 32, 71-5	44.5	92
39	Metabolomic adaptations and correlates of survival to immune checkpoint blockade. <i>Nature Communications</i> , <b>2019</b> , 10, 4346	17.4	89
38	gkmSVM: an R package for gapped-kmer SVM. <i>Bioinformatics</i> , <b>2016</b> , 32, 2205-7	7.2	87
37	Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study. <i>Genetics in Medicine</i> , <b>2016</b> , 18, 1011-9	8.1	84
36	Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer. <i>Cancer Discovery</i> , <b>2016</b> , 6, 1134-1147	24.4	81
35	Intermediate basal cells of the prostate: in vitro and in vivo characterization. <i>Prostate</i> , <b>2003</b> , 55, 206-18	4.2	81
34	Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 5708-13	11.5	78
33	Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants. <i>Cell Reports</i> , <b>2016</b> , 17, 1171-1183	10.6	78
32	Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. <i>Blood</i> , <b>2016</b> , 128, 1093-100	2.2	78
31	Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. <i>Cell</i> , <b>2018</b> , 173, 624-633.e8	56.2	71

30	The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. <i>Cancer Discovery</i> , <b>2020</b> , 10, 1174-1193	24.4	67
29	Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function Mutations. <i>Cancer Discovery</i> , <b>2017</b> , 7, 973-983	24.4	65
28	Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1. <i>PLoS ONE</i> , <b>2014</b> , 9, e101283	3.7	60
27	Prospective enterprise-level molecular genotyping of a cohort of cancer patients. <i>Journal of Molecular Diagnostics</i> , <b>2014</b> , 16, 660-72	5.1	57
26	Rapid Intraoperative Molecular Characterization of Glioma. <i>JAMA Oncology</i> , <b>2015</b> , 1, 662-7	13.4	53
25	Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. <i>Cancer Immunology Research</i> , <b>2015</b> , 3, 855-63	12.5	53
24	Inherited DNA-Repair Defects in Colorectal Cancer. <i>American Journal of Human Genetics</i> , <b>2018</b> , 102, 401-414	41.4	50
23	Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 2700-11	6.1	49
22	MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in -, and -Mutant Melanomas. <i>Cancer Discovery</i> , <b>2019</b> , 9, 526-545	24.4	41
21	Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. <i>JAMA Oncology</i> , <b>2015</b> , 1, 238-44	13.4	41
20	PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy. <i>Cancer Research</i> , <b>2015</b> , 75, 1944-8	10.1	40
19	Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis. <i>Molecular Cell</i> , <b>2018</b> , 71, 554-566.e7	17.6	40
18	A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. <i>Neuro-Oncology</i> , <b>2017</b> , 19, 774-785	1	37
17	Genetic modifiers of EGFR dependence in non-small cell lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 18661-6	11.5	37
16	Long-term drug administration in the adult zebrafish using oral gavage for cancer preclinical studies. <i>DMM Disease Models and Mechanisms</i> , <b>2016</b> , 9, 811-20	4.1	37
15	Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. <i>Genetics in Medicine</i> , <b>2017</b> , 19, 787-795	8.1	34
14	Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, E1296-305	11.5	33
13	Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States. <i>Cell Systems</i> , <b>2017</b> , 5, 105-118.e9	10.6	27

12	Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2016</b> , 14, 820-4	7.3	26
11	From integrated genomics to tumor lineage dependency. <i>Cancer Research</i> , <b>2006</b> , 66, 2506-8	10.1	26
10	Systematic genomic and translational efficiency studies of uveal melanoma. <i>PLoS ONE</i> , <b>2017</b> , 12, e0178139	3.9	21
9	Whole-genome sequencing and cancer therapy: is too much ever enough?. <i>Cancer Discovery</i> , <b>2012</b> , 2, 766-8	24.4	19
8	The fuzzy world of precision medicine: deliberations of a precision medicine tumor board. <i>Personalized Medicine</i> , <b>2017</b> , 14, 37-50	2.2	13
7	Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2183-9	12.9	10
6	Mechanisms of Resistance to Mitogen-Activated Protein Kinase Pathway Inhibition in BRAF-Mutant Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2012</b> , 680-4	7.1	6
5	Increased Local Disorder of DNA Methylation Forms the Basis of High Intra-Leukemic Epigenetic Heterogeneity and Enhances CLL Evolution. <i>Blood</i> , <b>2013</b> , 122, 596-596	2.2	4
4	On or off target: mutations, models, and predictions. <i>Science Translational Medicine</i> , <b>2010</b> , 2, 35ps28	17.5	2
3	An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes.. <i>Cancer Cell</i> , <b>2022</b> , 40, 524-544.e5	24.3	2
2	Inclusion of the ASH1 gene that governs the neuroendocrine differentiation of lung epithelium as an additional prototypic lineage-survival oncogeneS <i>Nature Reviews Cancer</i> , <b>2007</b> , 7, 68-68	31.3	
1	Mechanisms of resistance (MoR) to DNA damaging therapy (tx) in BRCA1/2-deficient (d) metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 542-542	2.2	